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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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TUESDAY, FEBRUARY 27, 2018

Overflow audience at 13th annual Huntington's
Disease Therapeutics Conference
With more than 350 Huntington’s disease researchers and pharmaceutical
executives in attendance, the 13th annual HD Therapeutics Conference got
underway last night in anticipation of key presentations on progress towards
treatments, including the successful Phase 1/2a Ionis Pharmaceuticals genesilencing clinical trial completed late last year.
Sponsored by CHDI Foundation, Inc., the nonprofit virtual biotech focused on the
search for HD treatments, the conference runs through March 1 at the Parker Palm
Springs hotel (which is less than three hours’ drive from my San Diego home). In
the last presentation, Ionis clinical trial administrators will present the results of
the Phase 1/2a study of the company’s HD, drug IONIS-HTTRx.
“The first day we opened up the registration, we were almost full at the Parker
immediately,” Robert Pacifici, Ph.D., CHDI’s chief scientific officer, said in his
opening remarks in the main conference room, which holds 300 people. “We
actually ended up allowing 365 participants to register. Not everybody can fit in
this room.” So, for the first time at the Parker, CHDI arranged for an overflow
room, with a screen projecting the proceedings.
After cancellations, a total of some 350 are expected to attend, one of the largest
audiences in the history of the conference.
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Dr. Pacifici also presented a check for $38,000 to Louise Vetter, the CEO of the
Huntington’s Disease Society of America (HDSA).
As a research organization, CHDI provides no family services such as support
groups and care centers. Demonstrating their commitment to HDSA’s mission in
these areas – essential for developing treatments – Dr. Pacifici and five other
riders (mainly from CHDI) raised the funds in a recent 100-mile biking
competition in the Southern California desert.
You can watch Dr. Pacifici’s introduction in the video below.
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CHDI Conference Opens
with Overflow Crowd
from Gene Veritas

14:07

CHDI
Conference Opens with Overflow Crowd from Gene Veritas on Vimeo.
‘Huntingtin lowering’ and other main themes
Scientists and patient advocates eagerly await the March 1 presentation of the
Ionis Phase 1/2a clinical trial, in which IONIS-HTTRx successfully lowered the
amount of the mutant huntingtin protein in participants’ cerebrospinal fluid.
The trial aimed not to study efficacy but safety and tolerability. The next phases of
the trial remain a major hurdle: to test whether the drug can actually alleviate or
reverse symptoms.
The Ionis contingent at the conference includes Frank Bennett, Ph.D., Ionis senior
vice president of research and the franchise leader for the company’s neurology
programs, and Anne Smith, Ph.D., the Ionis director of clinical development and
the individual responsible for the day-to-day management of the trial.
Dr. Smith will present the Ionis results along with Sarah Tabrizi, FRCP, Ph.D., of
University College of London, the lead clinical trial site.
In addition to so-called “huntingtin lowering” strategies such as the Ionis drug, the
main conference themes include potential therapies for fixing brain circuitry; the
use of stem cells to better understand HD and develop treatments; the interplay of
the huntingtin gene and DNA dynamics; and huntingtin protein structure and
function.
The opening day also featured a resource fair, with research tools and databases
available for HD research and developed by CHDI, partner organizations, and
contract research organizations.
(Disclosure: I hold a symbolic amount of Ionis shares.)
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Jen Ware, Ph.D., CHDI's director for experimental design (right), explains a new
CHDI research resource, the Independent Statistical Standing Committee,
intended to provide independent, unbiased evaluation and expert advice regarding
experimental design and statistics (photo by Gene Veritas).
Posted by Gene Veritas at 11:31 AM
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